جمعه 26 اردیبهشت 1404
[Archive]
دوره 30، شماره 138 - ( 10-1400 )
جلد 30 شماره 138 صفحات 72-69 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Nasiri A, Jahanifard E, Sharififard M, Arjmand R, Rasai S, Haeri T. Maggot Debridement Therapy (MDT) for Treatment of Cutaneous Leishmaniasis Wound using Lucilia serricata Larvae in Iran: Case Reports. J Adv Med Biomed Res 2022; 30 (138) :69-72
URL: http://journal.zums.ac.ir/article-1-6237-fa.html
URL: http://journal.zums.ac.ir/article-1-6237-fa.html
Maggot Debridement Therapy (MDT) for Treatment of Cutaneous Leishmaniasis Wound using Lucilia serricata Larvae in Iran: Case Reports. Journal of Advances in Medical and Biomedical Research. 1400; 30 (138) :69-72
چکیده: (111153 مشاهده)
Leishmaniasis is a worldwide vector-borne disease. The Cutaneous form of this disease leaves chronic wounds on the patient's skin. The purpose of this study was to treat cutaneous leishmaniasis woundsusing Lucilia serricata larvae. Leishman’s body was confirmed and Leishmania major was identified using PCR test in the samples of three patients in health center of Andimeshk County, southwest Iran during 2019-2020. The patients signed an informed consent form to receive maggot therapy. Five to ten sterile 1st instar larva of L. serricata per cm2 wound were inserted directly on the wounds in 48-hours intervals and bandaged with sterile saline gauze. Cutaneous leishmaniasis wounds were free of purulent secretion within 9-12 days. After 30- 45 days of treatment; the wounds were healed entirely without leaving scar tissues. The results showed larvae of L. sericata can significantly improve wound healing rate but it is recommended to evaluate this biotherapy method in more patients.
نوع مطالعه: گزارش موردی |
موضوع مقاله:
Clinical Medicine
دریافت: 1399/7/7 | پذیرش: 1399/10/20 | انتشار: 1400/8/26
دریافت: 1399/7/7 | پذیرش: 1399/10/20 | انتشار: 1400/8/26
فهرست منابع
1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, Jannin J, den Boer M, WHO Leishmaniasis Control Team. Leishmaniasis: worldwide and global estimates of its incidence. PloS one. 2012; 7(5): e35671. [DOI:10.1371/journal.pone.0035671] [PMID] [PMCID]
2. Sanei-Dehkordi A, Khamesipour A, Akbarzadeh K, Akhavan AA, Mohammadi AM, Mohammadi Y, Rassi Y, Oshaghi MA, Alebrahim Z, Eskandari SE, Rafinejad J. Anti Leishmania activity of Lucilia sericata and Calliphora vicina maggots in laboratory models. Exp. Parasitol. 2016; 170: 59-65. [DOI:10.1016/j.exppara.2016.08.007] [PMID]
3. Jahanifard E, Hanafi-Bojd AA, Nasiri H, Matinfar HR, Charrahy Z, Abai MR, Yaghoobi-Ershadi MR, Akhavan AA. Prone Regions of Zoonotic Cutaneous Leishmaniasis in Southwest of Iran: Combination of Hierarchical Decision Model (AHP) and GIS. J Arthropod Borne Dis. 2019; 13(3):310. [DOI:10.18502/jad.v13i3.1540] [PMID] [PMCID]
4. Polat E, Kutlubay Z, Sirekbasan S. Treatment of Glucantime-resistant/tolerant cutaneous leishmaniasis with Lucilia sericata larvae and its larval secretions: The first study in the world. Trop. Biomed. 2016; 33(4): 668-74.
5. Cruz-Saavedra L, Díaz-Roa A, Gaona MA, Cruz ML, Ayala M, Cortés-Vecino JA, Patarroyo MA, Bello FJ. The effect of Lucilia sericata and Sarconesiopsis magellanica derived larval therapy on Leishmania panamensis. Acta Trop. 2016; 164: 280-9. [DOI:10.1016/j.actatropica.2016.09.020] [PMID]
6. Kabiri M, Dayer MS, Ghaffarifar F. Therapeutic Effects of Lucilia sericata Larvae on Cutaneous Leishmaniasis Wounds Caused by Leishmania major using BALB/c Mice as Animal Model. JKUMS. 2017; 24(5): 389-96.
7. Laverde-Paz MJ, Echeverry MC, Patarroyo MA, Bello FJ. Evaluating the anti-leishmania activity of Lucilia sericata and Sarconesiopsis magellanica blowfly larval excretions/secretions in an in vitro model. Acta Trop. 2018; 177: 44-50. [DOI:10.1016/j.actatropica.2017.09.033] [PMID]
8. Sherman RA. Maggot versus conservative debridement therapy for the treatment of pressure ulcers. Wound Repair Regen. 2002; 10(4): 208-14. [DOI:10.1046/j.1524-475X.2002.10403.x] [PMID]
9. Arrivillaga J, Rodríguez J, Oviedo M. Preliminary evaluation of maggot (Diptera: Calliphoridae) therapy as a potential treatment for leishmaniasis ulcers. Biomedica. 2008; 28(2):305-10. [DOI:10.7705/biomedica.v28i2.102] [PMID]
10. Polat E, Cakan H, Aslan M, Sirekbasan S, Kutlubay Z, Ipek T, Ozbilgin A. Detection of anti- leishmanial effect of the Lucilia sericata larval secretions in vitro and in vivo on Leishmania tropica: first work. Exp Parasitol. 2012; 132(2): 129-34. [DOI:10.1016/j.exppara.2012.06.004] [PMID]
11. Cherniack EP. Bugs as Drugs, Part 1: Insects: the" new" alternative medicine for the 21st century. Alter Med Rev. 2010; 15(2):124-35.
12. Whitaker IS, Twine C, Whitaker MJ, Welck M, Brown CS, Shandall A. Larval therapy from antiquity to the present day: mechanisms of action, clinical applications and future potential. Postgrad Med J. 2007; 83 (980): 409-13. http://dx.doi.org/10.1136/pgmj.2006.055905 [DOI:10.1136/pgmj.2006.055905] [PMID] [PMCID]
13. Jaffary F, Nilforoushzadeh MA, Siadat A, Haftbaradaran E, Ansari N, Ahmadi E. A comparison between the effects of glucantime, topical trichloroacetic acid 50% plus glucantime, and fractional carbon dioxide laser plus glucantime on cutaneous leishmaniasis lesions. Dermatol Res Pract. 2016;1-4. http://dx.doi.org/10.1155/2016/6462804 [DOI:10.1155/2016/6462804] [PMID] [PMCID]
14. Paul AG, Ahmad NW, Lee HL, Ariff AM, Saranum M, Naicker AS, Osman Z. Maggot debridement therapy with Lucilia cuprina: a comparison with conventional debridement in diabetic foot ulcers. Int Wound J. 2009; 6(1):39-46. [DOI:10.1111/j.1742-481X.2008.00564.x] [PMID] [PMCID]
15. Gericke A, Hoffmann EM, Pitz S, Pfeiffer N. Maggot therapy following orbital exenteration. Br J Ophthalmol. 2007; 91(12):1715-6. [DOI:10.1136/bjo.2007.116673] [PMID] [PMCID]
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است. |
